Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Applications are Open for the 2026 Semmelweis-Richter Journalism Award Until June 9th28.5.2026 09:00:00 CEST | Press release
BUDAPEST, HUNGARY / ACCESS Newswire / May 28, 2026 / After the strong success of its first edition, the Semmelweis-Richter Journalism Award returns in 2026. Journalists from eligible European countries are invited to submit entries in two categories: Women's Health and Pharmaceutical Strategies and Innovation, with a special focus on cardiovascular therapies. The application deadline is June 9, 2026, 23:59 CET. The international award was first launched in 2025 by Semmelweis University, Hungary's leading medical and health sciences university, with the support of Gedeon Richter, a Hungary-based, innovation-focused multinational pharmaceutical company. The award aims to recognise high-quality health journalism and its role in informing the public and shaping health-related debate across Europe. The first edition attracted wide international interest, with nearly 70 submissions from more than 20 European countries, including the United Kingdom, Germany, and Russia. Entries were published
Miami Fashion Week Successfully Launches Inaugural Virtual Fashion Awards Gala at Queen Miami Beach27.5.2026 18:00:00 CEST | Press release
A groundbreaking evening celebrating the future of fashion through technology, creativity, and innovation brought together global designers, AI-powered runway premieres, and industry recognition. MIAMI, FL / ACCESS Newswire / May 27, 2026 / Miami Fashion Week (MIAFW) successfully hosted its inaugural Virtual Fashion Awards on May 21, 2026, at Queen Miami Beach, hosted by Emmy Award-Winning Journalist, Lisa Petrillo. The exclusive in-person event welcomed global fashion leaders, designers, and innovators for an evening dedicated to creativity, technology, and the evolving future of fashion. Blending physical and digital experiences, the gala featured both produced and in-development collections, highlighting the fusion of emerging technologies with traditional craftsmanship. A live model showcase complemented the AI-powered virtual runway presentations, creating a fully immersive experience for attendees. Images (Courtesy of Miami Fashion Week): here Official Gala Recap and Virtual Pres
OMP Launches Unison Express to Fast-Track Supply Chain Planning from Ambition to Early Value27.5.2026 15:00:00 CEST | Press release
Ready-to-deploy solution delivers value quickly through proven industry best practices ANTWERPEN, BE / ACCESS Newswire / May 27, 2026 / OMP, a leading provider of AI-powered supply chain planning solutions, today announced the launch of Unison Express - an industry-specific, ready-to-deploy planning offering for mid-market companies looking to move beyond the tools and processes they have outgrown. Unison Express enables teams to realize value quickly while establishing a strong planning foundation that scales with their business over time. From spreadsheets to structured planning Organizations across industries face mounting pressure to modernize supply chain planning. Yet implementation projects can feel long, costly, and difficult to justify, especially when teams still rely on tools and processes they have outgrown, such as spreadsheets, legacy systems, and manual coordination. The result is higher operational risk and slower, less coordinated decision-making. Unison Express bridge
SINTEF Selects Power to Hydrogen to Produce Green Hydrogen for the PYROCO2 EU Green Deal Project in Norway27.5.2026 10:35:00 CEST | Press release
Power to Hydrogen's Second Commercial Project Extends Industrial-Scale AEM Electrolysis Into Chemicals Manufacturing COLUMBUS, OH / ACCESS Newswire / May 27, 2026 / Power to Hydrogen (P2H2), a developer of anion exchange membrane (AEM) electrolyzer systems, today announced a binding commercial order from SINTEF, one of Europe's largest research institutes, for a half-megawatt AEM electrolyzer system scheduled to be delivered in Q4 2026. The system will be deployed at SINTEF's facility in Tiller, Norway, where it will produce green hydrogen for a novel gas fermentation process that combines green hydrogen and captured carbon dioxide to produce zero-emission acetone, a platform chemical used across solvents, plastics, and industrial value chains. The order is Power to Hydrogen's second commercial project, following the company's landmark project at the Port of Antwerp-Bruges - set to be commissioned this summer - and marks an important expansion of AEM electrolysis into green chemicals a
Caldwell Strengthens Consumer and Private Equity Capabilities with Addition of Gabino Stuyck in Madrid27.5.2026 09:30:00 CEST | Press release
TORONTO, ON AND MADRID, ES / ACCESS Newswire / May 27, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Gabino Stuyck as a Partner in the firm's Consumer Practice. Based in Madrid, Stuyck's appointment expands Caldwell's presence in Europe and strengthens the firm's capabilities across consumer, private equity, technology, sports, and digital transformation leadership assignments globally. Caldwell welcomes Gabino Stuyck as a partner in the firm's Consumer Practice, strengthening the firm's global consumer and private equity capabilities. Based in Madrid, Stuyck advises private equity firms, portfolio companies, and global organizations on senior executive and board appointments across Europe, the Middle East, Latin America, and North America. With more than 17 years of executive search experience and more than 200 completed mandates worldwide, he is recognized for building high-impact leadership teams in investor-backed, high-growth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom